Salmeterol
Salmeterol is a long-acting beta agonist (LABA) inhaled medicine that relaxes and opens air passages in the lungs. Salmeterol is used for Asthma, Exercise-induced bronchospasm and Chronic obstructive pulmonary disease.
Also called: Serevent (United Kingdom)
Pronunciation: pronunciation varies by local usage.
- Generic name
- salmeterol
- Brand names
- SEREVENT DISKUS, Serevent Accuhaler
- Drug class
- Long-acting beta agonist (LABA)
- Form
- Dry powder for oral inhalation using a specially designed inhaler
- Route
- Oral inhalation
- Legal status
- Prescription-only medicine
Availability and supply rules vary by country
Trade names by country: United States · United Kingdom · Canada · Australia · New Zealand
Australia: Serevent Accuhaler · Full directory
What salmeterol is and how it works
Salmeterol is a long-acting beta agonist (LABA) inhaled medicine that relaxes and opens air passages in the lungs. It is used for maintenance control of asthma in people also using an inhaled corticosteroid, for prevention of exercise-induced bronchospasm, and for maintenance treatment of chronic obstructive pulmonary disease (COPD). (1) (2) (3)
Salmeterol is not a rescue inhaler and is not used alone for asthma. Approved uses, minimum age, device, and product availability differ by country. A prescriber must confirm eligibility, inhaler technique, and whether the person has a short-acting rescue medicine.
Mechanism of action: how salmeterol works
Salmeterol is a long-acting beta agonist (LABA). It works by relaxing and opening air passages in the lungs, making it easier to breathe. (2) (1) (3)
What is Salmeterol used for?
Asthma
US label: salmeterol is indicated for treatment of asthma only as additional therapy with an inhaled corticosteroid in patients aged 4 years and older whose asthma is inadequately controlled on an inhaled corticosteroid. US label dose is 1 inhalation (50 mcg) twice daily, approximately 12 hours apart. AU ARTG indication: long-term regular treatment of reversible airways obstruction in asthma, including nocturnal and exercise-induced asthma, in patients aged 4 years or more who are receiving inhaled or oral corticosteroids. It should not be used if occasional short-acting beta-2 agonists are sufficient. (2) (3)
Exercise-induced bronchospasm
US label: salmeterol is indicated to prevent exercise-induced bronchospasm in patients aged 4 years and older. US label dose is 1 inhalation at least 30 minutes before exercise; additional doses should not be used for 12 hours, and people already using salmeterol twice daily should not use another dose before exercise. AU ARTG asthma indication includes exercise-induced asthma in patients aged 4 years and over who are receiving inhaled or oral corticosteroids. (2) (3)
Chronic obstructive pulmonary disease
US label: salmeterol is indicated for long-term twice-daily maintenance treatment of bronchospasm associated with COPD, including emphysema and chronic bronchitis. US label dose is 1 inhalation twice daily. AU healthdirect states salmeterol also provides long-lasting (12 hours) bronchodilation for the reversible component of airways obstruction due to COPD in adults. (2) (3)
Before taking salmeterol
Do not take / not appropriate for
- Do not use salmeterol alone for asthma. US label: use of salmeterol without a concomitant inhaled corticosteroid is contraindicated. (asthma) (2)
- Do not use salmeterol to treat sudden asthma attacks, acute bronchospasm, status asthmaticus, or acute episodes of asthma or COPD requiring intensive measures. It is not a rescue medicine. (all indications) (2) (1)
- Do not use salmeterol if you have severe hypersensitivity to milk proteins or known hypersensitivity to salmeterol or any of the product ingredients. (all products) (2)
Tell your clinician about
- Any allergy to salmeterol, other medicines, milk protein, or any food.
- Whether you use another long-acting beta agonist, such as arformoterol, formoterol, indacaterol, olodaterol, vilanterol, or a fluticasone/salmeterol combination product, because additional LABA medicines should not be used with salmeterol.
- Any current or recent use, within the past two weeks, of tricyclic antidepressants or monoamine oxidase inhibitors.
- Any history of irregular heartbeat, high blood pressure, QT prolongation, seizures, thyroid disease, diabetes, or ketoacidosis.
- All prescription and non-prescription medicines, vitamins, supplements, and herbal products.
- Pregnancy, plans for pregnancy, or breastfeeding.
Salmeterol dosage and how to take it
- Salmeterol is for oral inhalation only, using the dry-powder inhaler exactly as prescribed.
- US label for asthma and COPD: 1 inhalation twice daily, morning and evening, about 12 hours apart. For prevention of exercise-induced bronchospasm: 1 inhalation at least 30 minutes before exercise, not more often than once every 12 hours. If already using salmeterol twice daily, do not use another dose before exercise.
- Do not use more or less salmeterol or use it more often than prescribed.
- Do not use salmeterol to treat sudden breathing problems. Use the prescribed short-acting beta agonist rescue inhaler for sudden symptoms.
- Do not change the way you use any asthma or COPD medicine, including an inhaled corticosteroid or rescue inhaler, without advice from the prescriber.
- Before first use, ask the doctor, pharmacist, or respiratory therapist to show and watch your inhaler technique.
Procedures and treatment changes
Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1) (2) (3)
Missed dose
Gap in supplied research notes: MedlinePlus includes a missed-dose heading for salmeterol, but the specific instruction was not captured. Contact the prescriber or pharmacist for the exact next-step instruction.
Overdose
US FDA label: overdose can cause excessive beta-adrenergic stimulation or exaggeration of beta-agonist effects, including seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, muscle cramps, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, insomnia, hyperglycemia, hypokalemia, metabolic acidosis, QTc prolongation, ventricular arrhythmias, and possibly cardiac arrest or death. Seek emergency medical attention immediately. Treatment is clinician-managed: discontinuation of salmeterol together with appropriate symptomatic therapy may be needed. A cardioselective beta-receptor blocker may be considered by clinicians, but such medicine can produce bronchospasm. Cardiac monitoring is recommended. There is insufficient evidence to determine if dialysis is beneficial. (2)
Salmeterol side effects
Salmeterol can cause beta-agonist effects such as palpitations, chest pain, rapid heart rate, tremor, or nervousness. Immediate hypersensitivity reactions, including anaphylaxis, may occur after administration.
Fast, pounding, or irregular heartbeat; chest pain; tremor; nervousness
What to notice: Beta-agonist adverse effects may occur, especially with more frequent use or higher-than-prescribed use.
What to do: Tell the prescriber if these effects are troubling, severe, or accompanied by chest pain. Do not change the dose yourself. (2)
Worsening breathing or increased need for the rescue inhaler
What to notice: Rescue inhaler becomes less effective, more puffs are needed than usual, or lung function is decreasing.
What to do: Seek medical attention immediately rather than increasing salmeterol use yourself. (2) (1)
Worsening asthma or COPD
What to notice: Decreasing effectiveness of the short-acting rescue inhaler, need for more puffs than usual, four or more puffs per day of the rescue inhaler for two or more days in a row, use of more than one canister in an 8-week period, or significant decrease in lung function.
What to do: Contact the prescribing clinician immediately for reassessment. (1) (2)
Immediate hypersensitivity or anaphylaxis
What to notice: Hives, angioedema, rash, bronchospasm, low blood pressure, or anaphylaxis.
What to do: Seek emergency medical attention promptly and let the clinician you see advise whether to continue or stop salmeterol. (2)
Paradoxical bronchospasm
What to notice: Sudden wheezing or breathing difficulty shortly after inhaling salmeterol.
What to do: Seek prompt medical assessment. The clinician should decide whether to stop salmeterol and provide alternative therapy. (2)
Serious warnings
Asthma-related death with LABA monotherapy — boxed warning / contraindicated without inhaled corticosteroid
Symptoms: Use of salmeterol alone for asthma increases the risk of asthma-related death. LABA monotherapy also increases the risk of asthma-related hospitalization in pediatric and adolescent patients.
Action: Salmeterol must only be used for asthma together with an inhaled corticosteroid. Do not use salmeterol alone for asthma. (2)
Acute asthma or COPD attack — emergency
Symptoms: Severe or rapidly worsening breathing, poor response to the rescue inhaler, increasing rescue-inhaler use, or significant decrease in lung function.
Action: Use the prescribed short-acting beta agonist rescue medicine and seek immediate medical attention. Salmeterol is not for acute bronchospasm. (2) (1)
Immediate hypersensitivity and anaphylaxis — emergency
Symptoms: Hives, angioedema, rash, bronchospasm, low blood pressure, or anaphylaxis.
Action: Seek emergency medical attention promptly. Let the clinician you see advise whether to continue or stop salmeterol. (2)
Paradoxical bronchospasm — warning
Symptoms: Sudden wheezing or breathing difficulty shortly after inhalation.
Action: Seek prompt medical assessment. The clinician should decide whether to stop salmeterol and start alternative therapy. (2)
Cardiovascular, nervous system, or metabolic effects — warning
Symptoms: Palpitations, chest pain, rapid heart rate, tremor, nervousness, hypokalemia, or hyperglycemia. Caution is advised in cardiovascular or central nervous system disorders, convulsive disorders, thyrotoxicosis, diabetes mellitus, and ketoacidosis.
Action: Report symptoms and relevant medical conditions to the prescribing clinician. (2)
Interactions
| Medicine or test | Effect | Action |
|---|---|---|
| Other long-acting beta agonists | Using salmeterol with another LABA can increase the risk of overdose and adverse effects. | Tell the prescriber about all LABA medicines. The prescriber will decide which medicine should be used and which medicine should be stopped. (2) (1) |
| Tricyclic antidepressants and monoamine oxidase inhibitors | These medicines may interact with salmeterol; the prescriber should be told if they are being taken or were stopped within the past two weeks. | Give the prescriber and pharmacist a complete medication list. (1) |
| Inhaled corticosteroids and short-acting beta-agonist rescue inhalers | Salmeterol is not a substitute for an inhaled corticosteroid. Patients with asthma must continue their inhaled corticosteroid. Acute symptoms require a rescue short-acting beta agonist. | Do not change or stop these medicines without advice from the prescriber. (2) (1) |
| Cardioselective beta-receptor blockers | These medicines can produce bronchospasm if used, although a clinician may consider one judiciously in overdose. | Only a clinician should decide whether use is appropriate; do not self-treat. (2) |
Pregnancy, breastfeeding, kidney/liver function, age
Children and adolescents
US label: salmeterol is indicated for asthma and prevention of exercise-induced bronchospasm in patients aged 4 years and older. For patients younger than 18 years with asthma who need a LABA added to an inhaled corticosteroid, a fixed-dose combination product containing both an inhaled corticosteroid and a LABA should ordinarily be used. AU ARTG asthma indication also applies to patients aged 4 years and older. (2) (3)
Pregnancy and breastfeeding
US FDA label: available data from published epidemiological studies and case reports have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Beta-agonists may interfere with uterine contractility. Pregnant women with asthma should be closely monitored and medication adjusted to maintain optimal asthma control. AU healthdirect: seek advice from a doctor or pharmacist about the risks and benefits during pregnancy. Do not change asthma treatment without clinician advice. (2) (3)
Labor and delivery
US label: there are no adequate and well-controlled human studies evaluating salmeterol during labor and delivery. Use during labor should be restricted to patients in whom the benefits clearly outweigh the risks. (2)
Hepatic impairment
US label: monitor patients with hepatic impairment for signs of increased drug exposure. (2)
Severe milk protein allergy
US label: salmeterol is contraindicated in severe hypersensitivity to milk proteins. Anaphylactic reactions have been reported after inhalation of powder products containing lactose in people with severe milk protein allergy. (2)
Monitoring
Before starting
- Confirm the exact diagnosis, age, indication, and that asthma treatment includes an inhaled corticosteroid.
- Ask about allergy to salmeterol, milk protein, or product ingredients, and any previous immediate hypersensitivity reaction.
- Review use of other long-acting beta agonists, tricyclic antidepressants, MAO inhibitors, and the full medication list.
- Assess cardiovascular disorders, irregular heartbeat, high blood pressure, QT prolongation, seizures, thyrotoxicosis, diabetes, ketoacidosis, and hepatic impairment.
- Ensure the person has a prescribed short-acting beta agonist rescue inhaler and understands when to use it.
- Teach and observe inhaler technique before first use.
During treatment
- Monitor asthma control, COPD symptoms, rescue-inhaler use, and lung function.
- Seek medical advice immediately if a previously effective salmeterol dose fails to provide the usual response, because this may signal destabilization.
- Reassess whether continued salmeterol is still needed; once asthma is controlled, the prescriber may stop salmeterol while continuing the other asthma medicine.
- Watch for beta-agonist adverse effects, hypokalemia, hyperglycemia, paradoxical bronchospasm, and signs of increased drug exposure in hepatic impairment.
- Check inhaler technique, dose counter, storage, and the patient's understanding of not using salmeterol for acute symptoms.
Storage
AU label: store below 30 degrees Celsius in a dry place; shelf lifetime is 2 years. Keep the inhaler dry. Do not exhale into the inhaler, take it apart, or wash the mouthpiece or any part of the inhaler. Do not use the inhaler with a spacer.
Professional information
Clinician-facing context only. Use the current US FDA label or AU ARTG/CMI product information and applicable asthma/COPD guidelines.
United States
Indication: Asthma in patients aged 4 years and older
Dose summary: US label: 1 inhalation (50 mcg) twice daily, approximately 12 hours apart, in addition to concomitant inhaled corticosteroid. Not for use as monotherapy. If a previously effective regimen fails, seek medical advice immediately.
Renal context: Gap in supplied research notes: no renal-specific dosing guidance is provided. (2)
United States
Indication: Prevention of exercise-induced bronchospasm in patients aged 4 years and older
Dose summary: US label: 1 inhalation at least 30 minutes before exercise. Additional doses should not be used for 12 hours. Patients receiving salmeterol twice daily should not use additional salmeterol for prevention of exercise-induced bronchospasm.
Renal context: Gap in supplied research notes: no renal-specific dosing guidance is provided. (2)
United States
Indication: Maintenance treatment of bronchospasm associated with COPD
Dose summary: US label: 1 inhalation twice daily.
Renal context: Gap in supplied research notes: no renal-specific dosing guidance is provided. (2)
Australia
Indication: Asthma and COPD
Dose summary: AU ARTG asthma indication: long-term regular treatment of reversible airways obstruction in asthma, including nocturnal and exercise-induced asthma, in patients aged 4 years and over receiving inhaled or oral corticosteroids. AU healthdirect also states salmeterol provides long-lasting (12 hours) bronchodilation for the reversible component of COPD in adults. Product pack is Serevent Accuhaler 50 microgram/actuation powder for inhalation. The supplied notes do not provide a separate AU dose schedule; use the AU CMI/ARTG product information.
Renal context: Gap in supplied research notes: no renal-specific dosing guidance is provided. (3)
Hepatic guidance
US label: monitor patients with hepatic impairment for signs of increased drug exposure. No hepatic-specific dose adjustment is provided in the supplied notes.
Overdose note
US FDA label: overdose may show excessive beta-adrenergic stimulation and can prolong the QTc interval. Treatment is clinician-managed and may include discontinuation of salmeterol, symptomatic therapy, and cardiac monitoring. A cardioselective beta-receptor blocker may be considered by clinicians but can produce bronchospasm. Dialysis benefit is uncertain. (2) (1) (3)
Frequently asked questions
Can salmeterol be used alone for asthma?
No. US label: salmeterol is contraindicated for asthma without a concomitant inhaled corticosteroid because LABA monotherapy increases the risk of asthma-related death. (2)
Can I use salmeterol during an asthma attack or sudden breathing difficulty?
No. Salmeterol is not for acute bronchospasm. Use the prescribed short-acting beta agonist rescue inhaler and seek medical attention if symptoms do not improve or worsen. (2) (1)
How long before exercise should salmeterol be used?
US label: use 1 inhalation at least 30 minutes before exercise. Do not take another dose for 12 hours. If already using salmeterol twice daily, do not use an extra dose before exercise. (2)
I have severe milk protein allergy. Can I use salmeterol?
US label: salmeterol is contraindicated in severe hypersensitivity to milk proteins. Inhaled lactose-containing powder can cause anaphylactic reactions in people with severe milk protein allergy. (2)
What should I do if my rescue inhaler becomes less effective or I need more puffs?
Contact the prescribing clinician immediately. Decreasing rescue-inhaler effectiveness or increasing need may be a sign of worsening asthma or COPD and means the treatment regimen should be reassessed. (1) (2)
What is the mechanism of action of salmeterol?
Salmeterol is a long-acting beta agonist (LABA). It works by relaxing and opening air passages in the lungs, making it easier to breathe. (2) (1) (3)
References
- Salmeterol: MedlinePlus Drug InformationMedlinePlus, U.S. National Library of Medicine · United States · accessed 2026-10-13 · source 1
- SEREVENT DISKUS (salmeterol xinafoate) powder, metered - prescribing informationU.S. Food and Drug Administration (DailyMed) · United States · dated 2022 · accessed 2026-10-13 · source 2
- SEREVENT ACCUHALER salmeterol 50 microgram/actuation powder for inhalation blister pack - Consumer Medicine Informationhealthdirect Australia · Australia · accessed 2026-10-13 · source 3
Brand names by country
Single-ingredient salmeterol names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.
Priority countries
United States
- SEREVENT DISKUSpowder, metered · 50 ug · glaxosmithkline llcregulator source
United Kingdom
- Sereventreference source
- Neoventreference source
- Soltelreference source
Canada
- SEREVENT DISKHALER DISKregulator source
- SEREVENTregulator source
Australia
- Serevent Accuhalerreference source
New Zealand
- Serevent Accuhalerreference source
- Sereventreference source